Related Experiment Video
Updated: Jun 29, 2025
09:51
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
Published on: July 26, 2017
12.4K
TNFR2 signalling in inflammatory diseases
Richard O Williams1, Felix Il Clanchy1, Yi-Shu Huang1
1Kennedy Institute of Rheumatology, University of Oxford, Roosevelt Drive, Oxford, OX3 7FY, UK.
Best Practice & Research. Clinical Rheumatology
|March 27, 2024
Summary
Targeting tumor necrosis factor (TNF) receptors selectively offers new therapeutic strategies. Inhibiting TNFR1 may treat autoimmune diseases, while TNFR2 agonists could aid cancer therapy.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Tumor necrosis factor (TNF) signals through two receptors: TNFR1 and TNFR2.
- TNFR1 mediates pro-inflammatory effects, while TNFR2 is involved in immune homeostasis and tissue healing, but also tumor progression.
- Current anti-TNF biologics lack selectivity, inhibiting both TNFR1 and TNFR2.
Purpose of the Study:
- To explore the therapeutic potential of selective TNF receptor inhibitors.
- To investigate TNFR1 inhibition for autoimmune diseases and TNFR2 inhibition for cancer.
- To evaluate TNFR2 agonists as a potential therapeutic approach.
Main Methods:
- The study hypothesizes the selective inhibition of TNFR1 in autoimmune diseases.
- It explores the development of TNFR1-selective inhibitors and TNFR2-specific agonists.
- The research discusses the validation of these concepts for novel therapeutic strategies.
Main Results:
- Selective TNFR1 inhibition is hypothesized to alleviate inflammation and promote homeostasis in autoimmune diseases.
- TNFR2 signaling is proposed to proceed unimpeded with TNFR1 inhibition, aiding homeostasis.
- TNFR2-specific agonists are being explored for monotherapy or combination treatment.
Conclusions:
- Selective inhibition of TNF receptors presents a promising therapeutic avenue.
- TNFR1 antagonists could treat autoimmune conditions by reducing inflammation.
- TNFR2 agonists may offer new strategies for cancer treatment.
More Related Videos
Related Concept Videos
02:26NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
01:24T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:28Inflammatory Response
2.0K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.0K
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:16TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K